## For State Medicaid Directors

#### INCORRECT DESI INDICATOR--PLEASE CORRECT IMMEDIATELY

Subsequent to the mailing of the quarter 2/2004 URA file, we were alerted to the fact that there is a labeler, American Health Packaging, labeler 62584, repackaging Epidrin. They have incorrectly reported it to us as a non-DESI (DESI Code = 2) product. It should have been correctly reported as a DESI (DESI Code = 5) product. The NDC is **62584-0139-00**, **-01 and -18** (3 package sizes). Please make this correction to your MDR file immediately. The DESI indicator of "5" will be shown on these NDCs in the next URA file for quarter 3/2004 (sometime in mid-November, 2004).

#### **DELETION OF NON-DRUG PRODUCTS**

Attached is a list of non-drug products for several labelers. These products will be deleted from the MDRI file effective October 1, 2004. Since these products are not rebateable under the drug rebate program, they should be deleted from your state files beginning with 4Q2004.

#### UPDATED PAGES FOR THE OPERATIONAL TRAINING GUIDE

Attached is revised Page O3 of the Operational Training Guide to reflect a change to the mailstop for overnight/express maildelivery. The new mailstop is S3-18-03. Also, attached is a revised Page O2 to correct the drug rebate website and add a new policy staff member. Please replace these pages in your guide.

#### MAILING STATE QUARTERLY URA FILES

We have had several inquiries from states requesting that their quarterly URA file be sent to them through other than "regular" USPS mail. The physical files are generated by the computer facility staff with specific instructions on generating mailing labels, packaging the files and having them sealed and delivered to the CMS central mailroom for USPS pickup.

To pull one or two specific state packages from the mix and have special handling done would cause a delay in all other states getting their files in the most timely manner possible. Additional handling of these packages could also result in erroneous mailings. Therefore, requests for special handling (overnight delivery, using a service other than USPS, etc.) cannot be honored.

#### **NEW LABELERS**

<u>Labeler Name/Labeler Code</u>	Mandatory Coverage <u>Date</u>	Optional Coverage <u>Date</u>
Presutti Laboratories, Inc. (Labeler Code 66378)	10/01/2004	07/13/2004
Alliant Pharmaceuticals (Labeler Code 68188)	10/01/2004	06/04/2004
JSJ Pharmaceuticals (Labeler Code 68712)	10/01/2004	07/14/2004
Eyetech Pharmaceuticals, Inc. (Labeler Code 68782)	10/01/2004	4 07/29/2004

#### **REINSTATED LABELER**

Neil Laboratories, Inc., labeler code 60242, has signed a new rebate agreement and was reinstated in the drug rebate program effective July 1, 2004.

Contact information for new/reinstated labelers is attached for your convenience.

### **TERMINATED LABELERS**

The following labeler codes are being terminated effective October 1, 2004:

BD Becton Dickinson (Labeler Code 08290); Excelsior Medical Corp. (Labeler Code 63807); and D&K Healthcare Resources (Labeler Code 65759).

A copy of the current listing of the 91-day treasury bill auction rates beginning with the period June 16, 2003, is attached.

Please remember to direct your drug rebate questions to a staff member listed in section "O" of the <u>Medicaid Drug Rebate Operational Training Guide</u>.

/s/

Edward C. Gendron
Director
Finance, Systems and Budget Group

4 Attachments

cc:

All State Drug Rebate Technical Contacts All Regional Administrators

# PRODUCT DELETION LIST - EFFECTIVE OCTOBER 1, 2004

## Hillestad Pharmaceuticals, labeler code 10542, product codes:

0015 0055 0070 0075 0080 0190

Unico Holdings, labeler code 59640, product codes:

0001 0006 0007

Abbott Labs, labeler code 00074, product codes:

6470 6471

#### CMS DRUG REBATE PROGRAM

## Area Code 410

## **OPERATIONS**

Tamara Bruce	786-1519
Chris Holmes	786-3328
Karen Leshko	786-1291
Vince Powell (Technical Director)	786-3314
Sue Williams	786-3334

# **POLICY**

Christie Cahee	786-6614
Claire Hardwick	786-6777
Chris Hinds	786-4578
Kim Howell	786-6762
Christina Lyon	786-3332
Cindy Pelter	786-1176
Katiuscia Potier	786-1947
Marge Watchorn	786-4361
	706 2225 /706

Larry Reed/Deirdre Duzor (Co-Directors) 786-3325/786-4626

## **SYSTEM MAINTENANCE**

E-mail inquiries to: MDRtech@cms.hhs.gov

## **DISPUTE RESOLUTION PROGRAM**


Sue Gaston	786-6918
Tamara Bruce	786-1519
Diane Dunstan	303-844-7040


FAX 786-0390 – Operations/Systems 786-8534 - Policy

<u>WEBSITE</u> www.cms.hhs.gov/medicaid/drugs/drughmpg.asp

Rev. 8/04 **O2** 

# CMS MEDICAID DRUG REBATE MAILING ADDRESSES





Mail Stop S3-18-03
7500 Security Boulevard
Baltimore, Maryland 21244

**NOTE:** PLEASE DO NOT USE the express mail address to send general correspondence to CMS. The use of this mail stop for general correspondence will delay its delivery to the appropriate individual.

Rev. 7/04 O3

## WEEKLY U.S. T-BILL INVESTMENT RATE

weekly 91-day treasury bill auction rates

Date of	Invest.
Auction	Rate
06-16-03	0.854
06-23-03	0.830
06-30-03	0.903
07-07-03	0.907
07-14-03	0.895
07-21-03	0.911
07-28-03	0.964
08-04-03	0.964
08-11-03	0.960
08-18-03	0.964
08-25-03	0.997
09-02-03	0.988
09-08-03	0.951
09-15-03	0.947
09-22-03	0.953
09-29-03	0.953
10-06-03	0.939
10-14-03	0.923
10-20-03	0.939
10-27-03	0.960
11-03-03	0.960
11-10-03	0.951
11-17-03	0.951
11-24-03	0.946
12-01-03	0.943

Date of	Invest.	Date of	Invest.
Auction	Rate	Auction	Rate
01-12-04	0.887	08-09-04	1.497
01-20-04	0.891		
01-26-04	0.907		
02-02-04	0.939		
02-09-04	0.939		
02-17-04	0.931		
02-23-04	0.947		
03-01-04	0.957		
03-08-04	0.945		
03-15-04	0.961		
03-22-04	0.945		
03-29-04	0.961		
04-05-04	0.945		
04-12-04	0.929		
04-19-04	0.949		
04-26-04	0.985		
05-03-04	1.001		
05-10-04	1.078		
05-17-04	1.058		
05-24-04	1.066		
05-31-04	1.150		
06-07-04	1.251		
06-14-04	1.413		
06-21-04	1.336		
06-28-04	1.381		

12-08-03	0.915
12-15-03	0.903
12-22-03	0.884
12-29-03	0.901
01-05-04	0.939

07-05-04	1.344		
07-12-04	1.336		
07-19-04	1.352		
07-26-04	1.449		
08-02-04	1.490		

## **TOPICAL INDEX - STATE MEDICAID RELEASES 1 - 133**

TOPIC	RELEASE #
1A Drug Listing	11
Additional Copies of Releases to SMDs	40
Adjustment Code for Forms CMS-304 & CMS-304a	57
Allscrips Pharmaceuticals, Inc.	65, 68, 69
AMP Recalculations	107, 109, 110. 112
Bankruptcy - Drug Labelers	19, 61, 68
Best Price	17, 01, 00
To DSH Covered Entities	36
Under MPDIMA of 2003	128
Betaseron - Coverage & Reimbursement	38, 40
<u> </u>	
Bulk Transfer/Buy-Out of Major Pharm. Assets	54, 55
Calphron	76, 79
Caverject Coverage	55
Closure During Federal Furloughs	57
Compendia	70
Confidential Information Release	17
Constant Disputes by Drug Labelers	23
Contact Information	65, 92
CPI-U Information	09, 102
Dataset Name Changes on Quarterly Rebate Tapes	41
Deleted NDCs (non-rebatable)	123, 128
Dipyridamole Issue	26
Dispute Resolution:	
Definition	19
E-Mail Address	128
Issues	55, 65, 71, 86, 108
Meetings	104, 113, 117, 123, 129, 132
Process Stages	45
Transfer of Function	121
Web Site	122
Workgroup Survey Results	42
Dispute Resolutions	59
Drug Category Change	61, 76
Drug Efficacy Study & Implementation (DESI):	,
Change Effective Date	20
Change Schedule	18
Effective Date Revisions	23, 24
DRUGDEX, a new compendium	70
Drug Emporium, Inc. Effective Date	65
Duplicate Discount/Rebate Mechanism Implementation	33
<u>.</u>	97
Effective Date(s) of Rebate Agreements  Entered Nutritional Products Coverage	
Enteral Nutritional Products - Coverage	30
Enteral Products	19
Eon Labs Product	117
Experimental Drugs - Coverage	43

TOPIC RELEASE #

E-ilon of Money for Assessment & Noviko Charles of	
Failure of Manufacturers to Notify States of	62
Disputes or Pay Rebates	63
FDA/MDRI Data Match	107, 115
Generic Substitution Laws	67
Goldline OTC Vitamin	102
Haldol Rebates	75 25
Herceptin: Genentech New Product	85
HIPPA – Prescription Numbers	124
Hotline	53
HRSA Notice Published/Exclusion File	98, 101, 106
Improper Rebate Withholding/Interest Implications	114
Index for Drug Rebate Notes	31
Information Sharing	57
Interest Calculation under Section V(b)	29, 88, 98
Interest:	
Failure to Pay	65
When PPAs are Submitted	121
Internet:	
Home Page	61, 85, 105, 117
Prescription Reimbursement Information	123
Pharmacy Plus Demonstrations	123
Invoices:	
Correct Labeler Address	36
Format	03
Incomplete Drug Labeler Data	18
Incorrect Invoicing	26
Remittance Advice Report Survey	35
Submission	19
Submitting for Multiple Quarters	36
Submitting to Drug Labelers	28
Labeler Contact File Changes	26, 32, 128, 132
Lovenox Prefilled Syringes	91
LTE/IRS Drugs	26
Magnetic Media	
New Address for Shipping (Effective 6/1/95)	52
Rejections	15
Shipments	15, 23
Specification Revisions	14, 72, 73
Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	27
MDR Technical E-mail Address	124
Medical Supplies & Devices	03, 16, 26
Metric Conversion/Rounding	18
MMA of 2003	128, 130
Multiple Package Size-Pricing Inconsistency	123
New Drug Products	41
New Rebate Agreement Status	23
Non-Drug Products Coverage	132
Non-Drug Products Deleted	132, 133
TOPIC	RELEASE #

Novartis Rounding All URAs Back to 1991	117
OBRA '93	40
OIG Reports/Reviews	120
Overpayments Due to AMP Recalculations	57, 107
Personnel Changes	124, 130
PHS Drug Pricing Program	44
Point-of-Sale System (POS) in Pharmacies	85
Policy E-Mail Address	113, 117
Prior Authorization	55
Prior Period Adjustments	14, 16, 60, 87
Prior Period Adjustments - Eli Lilly & Company	37
Prior Quarter Adjustment Statement (PQAS) Approval	60
Proposed Discount Equal Access Legislation	51
Publication of Drug Rebate Regulations CMS-2175-FC	126
Publication of Drug Rebate Regulations MB-46-P	55
Quarterly Prices, Late Submission	33
Quarterly Reporting - Form CMS-64.r	40
Quarterly Tape Submission to CMS	60, 72, 130
Quarterly Update File	14
Questions and Answers	65
Rebate Agreements:	
Start Date Procedures	102
Separate/Supplemental	102
Rebate/Reimbursement Issues	64, 113
	,
Rebates:	
Calculation Formula	07
Calculation Formula	07 113
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs	113
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment	113 40
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs	113 40 94
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address	113 40 94 55
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval	113 40 94 55 30 60
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations	113 40 94 55 30
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs	113 40 94 55 30 60 129
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup	113 40 94 55 30 60 129 41
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA	113 40 94 55 30 60 129 41 48, 52, 53, 56
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group)	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers	113 40 94 55 30 60 129 41 48, 52, 53, 56 39
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group)	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers Special Advisory Group	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113 16
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers Special Advisory Group Special Study – Anti-Load Viral/AIDS Drugs	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113 16 102 53
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers Special Advisory Group Special Study – Anti-Load Viral/AIDS Drugs Staff Listing Staff Relocation	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113 16 102
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers Special Advisory Group Special Study – Anti-Load Viral/AIDS Drugs Staff Listing Staff Relocation Standard Summary Record Format	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113 16 102 53 52, 83
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers Special Advisory Group Special Study – Anti-Load Viral/AIDS Drugs Staff Listing Staff Relocation	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113 16 102 53 52, 83 13
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers Special Advisory Group Special Study – Anti-Load Viral/AIDS Drugs Staff Listing Staff Relocation Standard Summary Record Format State Application of the FUL Program	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113 16 102 53 52, 83 13 48
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers Special Advisory Group Special Study – Anti-Load Viral/AIDS Drugs Staff Listing Staff Relocation Standard Summary Record Format State Application of the FUL Program State Contact Information	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113 16 102 53 52, 83 13 48
Calculation Formula Drugs Purchased Through the FSS Less than Administrative Costs Nonpayment Partial Payments Remittance/Check Address Reconciliation of State Invoice (ROSI) Approval Recordkeeping Regulations Rejection of State Records Matching LTE Drugs Remittance Advice Report/Workgroup Rescission of Termination for Novopharm USA S-TAG (Systems Technical Advisory Group) Separate Rebate Agreements with Manufacturers Special Advisory Group Special Study – Anti-Load Viral/AIDS Drugs Staff Listing Staff Relocation Standard Summary Record Format State Application of the FUL Program State Contact Information State Coverage:	113 40 94 55 30 60 129 41 48, 52, 53, 56 39 85 38, 113 16 102 53 52, 83 13 48 23, 26, 41, 98

TOPIC RELEASE #

State Hearing Process	44
State Invoices Containing Universal Product Codes	51
State Pharmacy Assistance Programs-Revised Criteria	124
State Plan Amendment Requirement	47
State Quarterly URA Files (Mailing)	133
State Responsibility - Terminated Drugs	19
State Utilization Data Study (SUDS)	33
T-bill Rates	83, 86, 132
Termination Date (NDC)	79
Terminated/Deleted Records	44
Terminated Defeted Records Termination From Program	55
S .	64
Therapeutic Equivalency Code  Timely Respire of Tanas (Notices of Mailing)	
Timely Receipt of Tapes/Notices of Mailing Tolerance Threshold Clarification	45
	40
For Interest	48
Rebate Amount Adjustments	44
Training Guide	122, 124, 125, 130, 132, 133
Unit-Dose Packaging	15
Unit Per Package Size	03
Change for Beohringer Ingelheim Product	123
Unit Rebate Amount (URA):	
Additional Amounts in 3/1998 File	85
Edits	43
Erroneous Amounts	51
First-Time Reporting on State Tape	132
Incorrect Amounts for 1Q98	79, 80
Invoice when the Amount is Zero	44
New Rounding Method	98, 100, 101, 106
Recalculations	111
Unit Type:	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Revisions	32, 83
UPPS Less Than 1.0	19
UPPS Used for Calculating Utilization	61
Use of Information from Outside Sources	48
Utilization Adjustments for Prior Calendar Quarters	67, 72
Utilization Data:	- 1 , 1 -
Changes to Labelers	57
Corrections/Problems	18, 51, 72
Late Submission	18
Receipt	29, 31
Record Format	08, 13, 72
Set Naming Requirements	19
Tapes/Confirmation Letter	19, 30, 40, 45, 58, 72, 82
Transmitting Corrections/Adjustments to CMS	16, 40, 72
<u> </u>	
Utilization Tape Record Specification	67, 72, 73, 98, 105

TOPIC RELEASE #

#### Vaccine: Deletions 26 19, 23 Exclusions Policy Clarification 25 Viagra Coverage 81 Vitasert 64 Warrick Pharmaceuticals (Sodium Chloride Solution) 98 97 Xenical Coverage Y2K 72, 87